



Update on activities ECVAM

Thomas Hartung & ECVAM Team


*Institute for Health and Consumer Protection (IHCP)
Ispra (Va), Italy*

<http://ecvam.jrc.it>




ECVAM Mission


Directive 86/609/EEC



- Validation
- Database
- Research
- Communication
- ESAC



ECVAM
Reorganisation





The ECVAM Business Plan

- **A ten year program to meet the expectations from legislation**
- **Bundling of all stakeholder activities**
- **Combination of strategic and technical developments**
- **Estimated costs for test optimisation and (pre-) validation of 150 M€**
- **Adoptation of ECVAM's services already initiated**



Reorganization of staff

KEY AREAS

- **Systemic toxicity**
- **Topical toxicity**
- **Sensitisation**
- **Carcinogenicity**
- **Reproductive toxicity**
- **Toxicokinetics**
- **Ecotoxicology**
- **Biologicals**
- **SIS databases**
- **QSARs**
- **Strategic developments**
(GLP, GCCP, HTS, toxicogenomics)

ECVAM staff teams

(incl. 5 assistants)


plus laboratory activities

plus external experts



Staff 1999-2004

Joint Research Centre





Foreseen New Permanent Staff

Published posts

- Ocular Irritancy
- Biometry
- High-throughput Testing
- Biocompatibility
- QSAR
- Database (B)

Planned early 2004

- GLP / Labmanager
- E-learning
- Cell biology techn. (B)

5 assistants

- Cancer, endocrine disr., systemic tox., etc.



Topical Toxicity and Skin Sensitisation

| | Development | Prevalidation | Validation | ESAC statement | Regulatory acceptance |
|--------------------------------|-------------|---------------|-------------|----------------|-----------------------|
| Skin Corrosion | ✓ | ✓ | ✓ | ✓ | ✓ |
| Phototoxicity | ✓ | ✓ | ✓ | ✓ | ✓ |
| Skin Irritation | ✓ | ✓ | 2003 | | |
| Eye Irritation | ✓ | ✓ | 2004 | | |
| Skin Sensitisation | ✓ | | | ✓ | ✓ |
| Percutaneous Absorption | ✓ | | | | ✓ |




Example: Acute Systemic Toxicity

ICCVAM/ECVAM Validation

Joint Research Centre


Registry of
Cytotoxicity



ECVAM-ICCVAM

Joint Validation Study of two


In Vitro Basal Cytotoxicity Assays





Strategy to Replace Acute Toxicity Testing

Joint Research Centre



A-Cute-Tox

Application for an R&D integrated project

Joint Research Centre

Coordinator:
Dr. C. Clemedson

Steering Committee:
Dr. L. Risteli
Prof. J.V. Castell
Dr. J.A Vericat
Prof. B. Blaauboer
Dr. P. Prieto

- WP1: In vivo database
- WP2: In vitro database
- WP3: Testing strategy
Iterative amendments
- WP4: New endpoints
New cell systems
- WP5: Correctors - ADE
- WP6: Correctors - metabolism
- WP7: Correctors – target organ
 - 7.1 Neurotoxicity
 - 7.2 Nephrotoxicity
 - 7.3 Hepatotoxicity
- WP8: Technical optimisation of
the test strategy
- WP9: Prevalidation
- WP10: Management, dissemination
and exploitation of results

- 37 participants
- 14 States
- 17 Universities
- 10 SME
- 4 Research Institutes
- 2 Industries
- 2 Foundations
- JRC



Cell culture incubator 37°C

Chemical storage unit 4°C

Carousel for cell-culture plates

Exposure station

Waste disposal

Diluting station

Carousel for plates with serial dilutions of chemicals




Conclusions

- **A-Cute-Tox represents an extension of the ICCVAM/ECVAM validation and MEIC study approach towards a full replacement test strategy**
- **It is piloting strategies for systemic toxicities**
- **Similar strategies will have to be developed for other systemic toxicities**



Chronic Toxicity

- Workshop on Long-Term Toxicity Testing (1999)
- Pilot study (flow-cell bioreactor, static-cell bioreactor)



- Evaluation of a new perfusion system developed in FP4
 - ongoing prevalidation
 - PREDICTOMICS
 - Workshop 2004





Development of in vitro systems predicting long-term toxicity in humans

- **Development of advance cell culture systems: liver and kidney**
 - ✓ co-cultures
 - ✓ targeted cell transformation
 - ✓ stem cell technology
 - ✓ organotypic cell cultures
- **To identify specific early mechanistic markers of toxin induced cell alterations: genomic, proteomic and cytomic analysis**
- **To establish and prevalidate a screening platform predictive of toxin induced chronic liver and renal diseases.**



PREDICTOMICS

Coordinator:
Prof. Jose V. Castell

Executive board:
Prof. Jose V. Castell
Prof. Walter Pfaller
Dr. Bernt Garthoff (ECOPA)
Prof. Thomas Hartung (ECVAM)

- 14 participants
- 8 States
- 6 Universities
- 2 SME
- 4 Industries
- 1 Foundation
- JRC

WP1: Liver cell model developments

- Innovated 3D culture technology
- Hepatocyte cell differentiation
- Stem cell technology

WP2: Kidney cell system developments

- Primary cultures, mono- and co-cultures
- New perfusion culture techniques
- Molecular biology studies on kidney differentiation

WP3: Optimisation of analysis tools

- Genomics
- Proteomics
- Cytomics

WP4: Mechanistically based gene markers identification (liver)

- Exposure to model toxicants
- Analysis of effects related to the mechanisms of toxicity
- Identification of marker genes

WP5: Mechanisms of nephrotoxicity and identification of toxicity markers

- Exposure to toxins and co-factors
- Analysis of activated genes
- Identification of mechanistically relevant marker genes and novel endpoints


WP6: Database generation. Analysis of model predictivity. Prevalidation






Reproductive Toxicology

- 2002 Validation of three embryotoxicity tests
2003 Workshop Regulatory Use
- Human embryonic stem cells in ECVAM
- 2003 Prevalidation Leydig cells
- Integrated project **ReProTect**
(35 partners, granted 9 M€)
- Review tests for endocrine disruptors (OECD)
Taskforce (Inventory, 2004: Prevalidations)






“**Reproductive Toxicology**”

“**Protection of Animals**”

“**Detection of reproductive toxicants**”



- OECD TG 414
- OECD TG 415
- OECD TG 416**
- OECD TG 421
- OECD TG 422
- OECD TG 426
- OECD TG 478
- OECD TG 483


- Directive 67/548/ EEC B22
- Directive 67/548/ EEC B23
- Directive 67/548/ EEC B31
- Directive 67/548/ EEC B34
- Directive 67/548/ EEC B35
- Directive 67/548/ EEC B22
- Directive 67/548/ EEC B23

- Fertility segment I
- Embryotoxicity/ Teratogenicity segment II
- Pre-postnatal Toxicity segment III



Structure of the ReProTest


Joint Research Centre



Management of the ReProTect



Joint Research Centre




| Science | Technology | Strategy | Exploitation |
|----------------------|-------------------|-------------|-------------------|
| Fertility | QSAR | Conference | Training |
| Prenatal development | Array technology | Workshops | Train the trainer |
| Implantation | Sensor technology | Task forces | e-learning |
| | Biometry | Regulators | |
| | | Industry | |



Breakdown of costs

Joint Research Centre




Total costs: > 16 Mio Euro
Requested funding: 12 Mio Euro





The consortium




35+ partners with complementary expertise






First EU sponsored project using human embryonic stem cells

- The used embryonic stem cell line has been established more than 5 years ago
- No additional human embryos need to be used
- Advice of the European group on Ethics in Science and New Technologies:
.....Culturing of specific cell lines to be used for pharmacological studies and toxicological testing is the most likely immediate biomedical application, making possible the rapid screening of large numbers of chemicals.....”





Joint Research Centre





Further ECVAM-ICCVAM efforts not covered today:

OECD GLP draft guidance document

Validation skin irritation & ocular irritancy

Workshops toxicogenomics & metabolism




Carcinogenicity

(Animal test: 1 M€)

Focus on non-genotoxic agents

**Establishment of
Cell Transformation Assay**



**2004:
(Pre)validation**

**2003:
Toxicogenomics
(Pilot study,
Workshop)**

